Analyzing BioNxt Solutions (OTCMKTS:BNXTF) and PainReform (NASDAQ:PRFX)

BioNxt Solutions (OTCMKTS:BNXTF) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for BioNxt Solutions and PainReform, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNxt Solutions	0	0	0	0	0.00
PainReform	1	0	0	0	1.00

Profitability

This table compares BioNxt Solutions and PainReform’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNxt Solutions	N/A	N/A	-879.46%
PainReform	N/A	N/A	N/A

Volatility and Risk

BioNxt Solutions has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, PainReform has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Valuation & Earnings

This table compares BioNxt Solutions and PainReform”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNxt Solutions	$20,000.00	1,531.13	-$5.43 million	($0.05)	-5.00
PainReform	$20,000.00	69.60	-$5.02 million	($736.66)	0.00

BioNxt Solutions is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

37.3% of PainReform shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

PainReform beats BioNxt Solutions on 7 of the 9 factors compared between the two stocks.

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.